Related Experiment Video
Updated: Jan 7, 2026
07:37
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
3.5K
Case report of intracranial tumor with serum MOG-IgG positivity
Zhuo Min1, Lingru Wang1, Yulai Kang2
1Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Army Medical Centre of People's Liberation Army (PLA), Army Medical University, Chongqing, China.
Frontiers in Immunology
|December 29, 2025
Summary
Serum myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) positivity can mimic inflammatory disorders. This case highlights the need to consider intracranial tumors in atypical MOG-IgG cases to prevent misdiagnosis.
Area of Science:
- Neurology
- Immunology
- Oncology
Background:
- Myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) positivity is associated with inflammatory demyelinating disorders.
- Distinguishing MOG-IgG associated conditions from other central nervous system pathologies can be challenging.
Purpose of the Study:
- To investigate the correlation between intracranial tumors and serum MOG-IgG positivity.
- To emphasize the importance of avoiding misdiagnosis in such cases.
Main Methods:
- A case report of a 24-year-old male with neurological symptoms and serum MOG-IgG positivity.
- Evaluation of central nervous system lesions using multimodal imaging and therapeutic response.
Main Results:
- The patient presented with MOG-IgG positivity and an upward trend in titers.
- Immunotherapy provided only temporary disease control.
- A final diagnosis of malignant intracranial tumor was established based on imaging and clinical course.
Conclusions:
- Serum MOG-IgG positivity and initial immunotherapy response can be misleading, mimicking inflammatory demyelinating disorders.
- Clinicians must consider central nervous system space-occupying lesions in atypical or refractory MOG antibody-associated disease.
- Vigilance for intracranial tumors is crucial to prevent diagnostic errors.
